On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having high expressions of PD-L1 (>50%) and no changes in EGFR or [...]
On May 15, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level equal to or greater than 1% for [...]
On May 6th, 2020, the Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET. The FDA based their approval on the results of the clinical trial [...]
by Amy C. Moore, PhD, Director, Science & Research, GO2 for Lung Cancer Patients with lung cancer face the challenge of drug resistance, while researchers focus on extending treatment duration. In collaboration with the patient group ALK Positive, we [...]
On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no [...]
SAN CARLOS, Calif., Dec. 3, 2019 -- GO2 for Lung Cancer announced the recipients of the 2019 Young Innovators Team Awards (YITA) today. Two teams of researchers received grants totaling $500,000 for their work developing novel strategies to treat KRAS-mutant non-small cell lung cancer (NSCLC) [...]
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor [...]
The GO2 for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care” – individuals and organizations that advance [...]
By Erik Hale When I was just 30 years old I was diagnosed with stage 3A adenocarcinoma, non-small cell lung cancer. After diagnosis I spent six weeks going through radiation and chemotherapy treatment to reduce the tumor size before going in [...]